Investigational genome editing therapy in clinical trial for Hunter syndrome
This week, a 40-year-old patient was treated at UNC's Clinical and Translational Research Center (CTRC) with SB-913, an investigational genome editing therapy for individuals with mucopolysaccharidosis type II (MPS II), a ...
Mar 22, 2018
0
17